Live tape
Top 8, mentions 7d183GOOGL30 mentions+0.01INTC29 mentions▲ +0.16NVDA27 mentions▲ +0.08SPY22 mentions+0.00VOO20 mentions▲ +0.04NKE19 mentions-0.01RBA19 mentions▲ +0.05MSFT17 mentions▲ +0.05

Equity · Healthcare

VRCA

Verrica Pharmaceuticals Inc. · NasdaqCM

$5.55 −1.07% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 17 sessions
$7.0 $5.5 24 Jun 17 Jul

The line runs $6 on 24 June through $5.55 on 17 July, on a scale from $5.5 to $7.0. Days the market did not trade hold the previous close, flat.

The chart above plots the price of VRCA over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 17 sessions over that window: $6 on 24 June 2026 through $5.55 on 17 July 2026.

Market cap $95.3M
52-week range $3.32 – $9
Avg volume 5.7K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 21, 2026

VRCA insider trades

SEC Form 4 · last 90 days · newest reported trade 18 Aug 2026
Open-market buys 6
Open-market sells 0
Net bought $211K
Non-trade filings 0
Date Insider Type Shares Value
18 Aug 2026 Kirby John J. Interim CFO Buy 5,000 $25K
18 Aug 2026 Rosenberg Noah L. CMO Buy 2,030 $10K
17 Aug 2026 Rieger Jayson CEO and President Buy 5,000 $25K
17 Aug 2026 Rosenberg Noah L. CMO Buy 4,200 $21K
17 Aug 2026 Zawitz David Chief Operating Officer Buy 6,000 $30K
14 Aug 2026 Rieger Jayson CEO and President Buy 20,000 $101K

VRCA reported financials

SEC EDGAR XBRL

VRCA reported revenue of $35.6M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$17.9M.

Figure Reported Period
Revenue $35.6M 31 Dec 2025 fiscal year
Net income −$17.9M 31 Dec 2025 fiscal year
Diluted EPS −$1.68 31 Dec 2025 fiscal year
Total assets $36.0M 30 Jun 2026 at period end
Total equity $4.3M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

VRCA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.62 $6M
31 Mar 2026 Q1 2026 $-0.45 $5M
31 Dec 2025 FY 2025 $-1.68 $36M
30 Sep 2025 Q3 2025 $-0.03 $14M
30 Jun 2025 Q2 2025 $0.02 $13M
31 Mar 2025 Q1 2025 $-1.03 $3M
31 Dec 2024 FY 2024 $-14.78 $8M
30 Sep 2024 Q3 2024 $-4.88

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

VRCA institutional holders

SEC Form 13F

2 of the 45 institutional funds we track reported a VRCA position for the quarter ended 30 Jun 2026 — a combined $383K; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Two Sigma Investments Held (±25%) −19.4% shares 40,825 $250K
Renaissance Technologies Trimmed −32.7% shares 21,769 $133K
Marshall Wace Exited

Source: SEC EDGAR 13F filings

VRCA fails-to-deliver

SEC CNS data

On 31 Aug 2026, 70,000 shares of VRCA failed to deliver (about $398K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 70,000 $398K 0.407%

Source: SEC fails-to-deliver (CNS) data